BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 23028720)

  • 21. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation and function of the epidermal growth factor receptor and erbB-2 during mammary gland morphogenesis.
    Sebastian J; Richards RG; Walker MP; Wiesen JF; Werb Z; Derynck R; Hom YK; Cunha GR; DiAugustine RP
    Cell Growth Differ; 1998 Sep; 9(9):777-85. PubMed ID: 9751121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissimilar effects of LY 294002 and PD 098059 in IGF-I-mediated inhibition of TGF-beta1 expression and apoptosis in bovine mammary epithelial cells.
    Zarzyńska J; Motyl T
    J Physiol Pharmacol; 2005 Jun; 56 Suppl 3():181-93. PubMed ID: 16077202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells.
    Soriano JV; Pepper MS; Nakamura T; Orci L; Montesano R
    J Cell Sci; 1995 Feb; 108 ( Pt 2)():413-30. PubMed ID: 7768990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.
    Liska D; Chen CT; Bachleitner-Hofmann T; Christensen JG; Weiser MR
    Clin Cancer Res; 2011 Feb; 17(3):472-82. PubMed ID: 21098338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells.
    Yanochko GM; Eckhart W
    Breast Cancer Res; 2006; 8(2):R18. PubMed ID: 16584539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.
    Bade LK; Goldberg JE; Dehut HA; Hall MK; Schwertfeger KL
    J Cell Sci; 2011 Sep; 124(Pt 18):3106-17. PubMed ID: 21868365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
    Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
    Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The involvement of the docking protein Gab1 in mitogenic signalling induced by EGF and HGF in rat hepatocytes.
    Aasrum M; Ødegård J; Sandnes D; Christoffersen T
    Biochim Biophys Acta; 2013 Dec; 1833(12):3286-3294. PubMed ID: 24126105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Action of methyl-, propyl- and butylparaben on GPR30 gene and protein expression, cAMP levels and activation of ERK1/2 and PI3K/Akt signaling pathways in MCF-7 breast cancer cells and MCF-10A non-transformed breast epithelial cells.
    Wróbel AM; Gregoraszczuk EŁ
    Toxicol Lett; 2015 Oct; 238(2):110-6. PubMed ID: 26253279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
    Castro NE; Lange CA
    Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
    Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
    Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
    Li Y; Huang X; Zhang J; Li Y; Ma K
    Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ADAM17-amphiregulin-EGFR axis in mammary development and cancer.
    Sternlicht MD; Sunnarborg SW
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):181-94. PubMed ID: 18470483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells.
    Beristain AG; Narala SR; Di Grappa MA; Khokha R
    J Cell Sci; 2012 Feb; 125(Pt 4):943-55. PubMed ID: 22421365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase.
    Vaught D; Chen J; Brantley-Sieders DM
    Mol Biol Cell; 2009 May; 20(10):2572-81. PubMed ID: 19321667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
    Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
    Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
    Castoldi R; Ecker V; Wiehle L; Majety M; Busl-Schuller R; Asmussen M; Nopora A; Jucknischke U; Osl F; Kobold S; Scheuer W; Venturi M; Klein C; Niederfellner G; Sustmann C
    Oncogene; 2013 Dec; 32(50):5593-601. PubMed ID: 23812422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.